Keyword: Lonza


Lonza Completes HPAPI Expansion at Visp

29.09.2022 -

Lonza has completed of the expansion of its Highly Potent API (HPAPI) multipurpose suite at the Basel-based CDMO’s alpine production site in Visp, Switzerland, adding...


Lonza and Touchlight Collaborate on DNA

08.09.2022 -

Lonza has entered into a collaboration with Touchlight, a biotechnology company with patented technology for producing enzymatic DNA. The enzymatic manufacturing process...


Lonza Builds Swiss Fill & Finish Facility

08.07.2022 -

Swiss CDMO Lonza plans to build a large-scale commercial fill & finish facility in Stein. The new facility, to be located on the same campus as Lonza’s existing clinical...


Samsung Biologics in $81 Million Deal with Novartis

13.06.2022 -

In the their first-ever collaboration, South Korea’s Samsung Biologics and Switzerland’s Novartis have inked an initial $81 million contract manufacturing and development...


Lonza and Israel Biotech Fund Collaborate

30.05.2022 -

Lonza and Israel Biotech Fund (IBF) have signed a framework agreement, under which the Swiss CDMO will provide advice and support for Israeli biotech companies. IBF is...

Chemistry & Life Sciences

Integrated Drug Development Models

13.05.2022 -

Interview with Giovanna Libralon, Senior Director Commercial Development Small Molecules at Lonza.


Germany’s Merck Takes Lonza’s MAST Platform

06.04.2022 -

Germany’s Merck has acquired Lonza’s Modular Automated Sampling Technology (MAST) platform for an undisclosed sum. The Darmstadt-based chemicals, pharmaceuticals and life...


Lonza to Manufacture Oasmia’s Ovarian Cancer Drug

22.03.2022 -

Swiss CDMO Lonza has signed an agreement for the large-scale manufacture of the main drug intermediate for Swedish specialty pharma Oasmia’s investigational cancer drug...